### **Supplementary Material**

# Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

Saxon D Smith<sup>1</sup>, Alexandros Stratigos<sup>2</sup>, Matthias Augustin<sup>3</sup>, Jose Manuel Carrascosa<sup>4</sup>, Susanne Grond<sup>5</sup>, Elisabeth Riedl<sup>6</sup>, Wen Xu<sup>5</sup>, Himanshu Patel<sup>5</sup>, Mark Lebwohl<sup>7</sup>

<sup>1</sup> ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia

<sup>2</sup> Department of Dermatology, University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece

<sup>3</sup> Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>4</sup> Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona,

Universidad Autónoma de Barcelona, IGTP, Badalona Spain

<sup>5</sup> Eli Lilly and Company, Indianapolis, IN, USA

<sup>6</sup> Department of Dermatology, Medical University of Vienna, Vienna, Austria

<sup>7</sup> Department of Dermatology, Mount Sinai Hospital, New York, NY, USA

### Corresponding author:

Saxon D Smith

ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia Email: dr.saxon.smith@gmail.com

#### Supplemental Figure 1. Designs and numbers of patients for all studies included in

#### the analysis.

I1F-MC-RHAG	5-150 mg IXE Q2W/PBO			
R, DB, dose-escalation (N=37)	Day 29	Day 141		
I1F-MC-RHBU* OL, pharmacokinetics (N=27)	160 mg IXE <sup>®</sup> 80 mg IXE Q2W Day 15 Wk 12			
I1F-MC-RHBN <sup>*</sup> <i>OL, R, pharmacokinetics</i> (N=32)	0	Q2W/Q4W	Wk 48	
I1F-MC-RHAJ <sup>↑</sup> <i>R, DB, dose-ranging, LTE-OL</i> (N=137)	10-150 mg IXE Q4W	Withdrawal <sup>b</sup> → 120 mg → 80 mg IXE Q4W <sup>c</sup>	//	
UNCOVER-1*	80 mg IXE	80 mg IXE Q4W/Q12W/Withdrawal (	(PBO)	
controlled, LTE	Wk 12	80 mg IXE Q4W Re-treatme	nt Wk 60	Wk 2
UNCOVER-2* R, DB, induction-PAC, LTE		: 16	(PBO)	Wk 2
(N=1171)	Wk 12	80 mg IXE Q4W Re-treatme	ent Wk 60	Wk 2
UNCOVER-3* R, DB, induction-PAC, LTE-O (N=1314) IXORA-P <sup>†</sup> R, DB	00 IXE \//	16	Wk 60 E Q4W	Wk 2
	Wk 12 80 mg IXE Q4W <sup>d</sup> IXE Q2W	80 mg IXE Q4W, <sup>e</sup> IXE Q2W, IXE Q4W <sup>d</sup> /IXE 0	Q2W <sup>e</sup>	Wk 2
(N=1255)			Wk 52	
IXORA-S <sup>+</sup> R, blinded, induction-AC (N=135)	80 mg IXE Q2W, UST	80 mg IXE Q4W, UST <sup>d</sup>	Drug-free Follow-up	
IXORA-Q <sup>†</sup> R. DB. induction-PBO-	WK 12			
controlled, EP-OL (N=140)	80 mg IXE Q2W/PBO	80 mg IXE Q4W <sup>f</sup>		
UNCOVER-A*	80 mg IXE Q2W	80 mg IXE Q4W		
(N=204)	Wk 12	80 mg IXE 04W	Wk 52	
UNCOVER-J* Single-arm, OL, LTE (N=91)	Wk 12		<u> </u>	E Q4W Wk 192
I1F-US-RHBO* <sup>5</sup>	80 mg IXE Q4W, IXE Q2W	80 mg IXE Q4W	•	
(N=12)	Wk 12		Wk 48	
I1F-EW-RHBZ <sup>†</sup> <i>R, OL, AC, EP</i> (N=104)	80 mg IXE Q2W/FAE/MTX 80	Mg IXE Q4W/FAE/MTX		
I1F-MC-RHBH <sup>+</sup> 160 mg	g IXE <sup>9</sup> 80 mg IXE Q2W/Q4W/PBO	80 mg IXE Q4W/PBO	0	
R (N=431)	Wk 12		Wk 60	
IXORA-R <sup>¥</sup> 160 mg <i>R, DB, AC</i> (N=519)	/GUS	<u> </u>		
11F-JE-RHCV <sup>¥</sup> <i>R, OL</i> (№=12.)				
	I1F-MC-RHBU*     OL, pharmacokinetics     (N=27)     I1F-MC-RHBN*     OL, R, pharmacokinetics     (N=27)     I1F-MC-RHBN*     OL, R, pharmacokinetics     (N=32)     I1F-MC-RHAJ*     R, DB, dose-ranging, LTE-OL     (N=137)     UNCOVER-1*     R, DB, induction-PBO-controlled, LTE     (N=1271)     UNCOVER-2*     R, DB, induction-PAC, LTE-OL     (N=1171)     UNCOVER-2*     R, DB, induction-PAC, LTE-OL     (N=1314)     IXORA-9*     R, DB, induction-PAC, LTE-OL     (N=1314)     IXORA-9*     R, DB, induction-PAC, LTE-OL     (N=135)     IXORA-9*     R, DB, induction-PBO-controlled, EP-OL     (N=140)     UNCOVER-4*     R, OL, 2 drug delivery system:     (N=204)     UNCOVER-4*     R, OL, 2 drug delivery system:     (N=204)     UNCOVER-1*     Single-arm, OL, LTE     (N=410)     <	IIF-MC-RHBU' OL, pharmacokinetics (N=27) 160 mg IXE $^{\circ}$ 80 mg IXE 02W Day 15 Wk 12   IIF-MC-RHBN' OL, R, pharmacokinetics (N=32) 80 mg IXE 160 mg NE 160 mg IXE 160 mg IXE   IIF-MC-RHBN' OL, R, pharmacokinetics (N=32) 10-150 mg IXE 04W 1000 mg IXE 1000 mg IXE 1000 mg IXE   IIF-MC-RHAJ <sup>+</sup> R, DB, dose-ranging, LTE-OL (N=137) 10-150 mg IXE 04W Wk 20 Wk 20 Wk 20   UNCOVER-1* R, DB, induction-PBO- controlled, LTE (N=1271) 1000 mg IXE 0000 mg IXE 0000 mg IXE 0000 mg IXE   UNCOVER-2* R, DB, induction-PAC, LTE-OL (N=1314) 80 mg IXE 000 mg IXE 0000 mg IXE <	IIF-MC-RHBU* OL, pharmacokinetics (N=27) 160 mg IXE* 80 mg IXE 20W Day 15 160 mg IXE 20W Day 15 30 mg IXE 20W WK 20   IIF-MC-RHBN* OL, R, pharmacokinetics 80 mg IXE 190 mg IXE 190 mg IXE 20 mg IXE   IIF-MC-RHBN* OL, R, pharmacokinetics 80 mg IXE 190 mg IXE 190 mg IXE 20 mg IXE   IIF-MC-RHAJ1 0 10-150 mg IXE 04W Wk 20 Wk 28   IIF-MC-RHAJ1 0 10-150 mg IXE 04W Wk 12 80 mg IXE 04W*   INCOVER-1* R, D8, induction-PBC, LTE-OL (N=137) 0 10-150 mg IXE 80 mg IXE 04W Re-treatme WK 12 80 mg IXE 04W/Re-treatme WK 12 80 mg IXE 04W/Re-treatme WK 12   INCOVER-3* R, D8, induction-PAC, LTE-OL (N=1314) WK 12 80 mg IXE 04W/IXE 02W, WK 12 80 mg IXE 04W/IXE 02W, WK 12   IXORA-F* R, D8, induction-PAC, LTE-OL (N=135) WK 12 80 mg IXE 04W/IXE 02W, WK 12 80 mg IXE 04W/IXE 02W, WK 12   IXORA-F* R, D8, AG induction-PBC- controlled, induction-PBC- controlled, induction-PBC- controlled, induction-PBC- controlled, induction-PBC- controlled, induction-PBC- controlled, induction-PBC- controlled, induction-AC 80 mg IXE 02W/IXE 02W 80 mg IXE 04W/IXE 02W   IXORA-F* R, D2, 2 drug delivery systems (N=204) 80 mg IXE 02W/IXE 02W 80 mg IXE 04W	IT-MC-RHBU* OL, <i>pharmacokinetics</i> 150 mg IXE 20W (N=27)   150 mg IXE 20W (N=27)

. <sup>a</sup> For patients receiving IXE, the starting dose was 160 mg at Wk 0 prior to receiving 80 mg IXE (Q4W or Q2W); <sup>b</sup> Withdrawal period (Wks 20-32); patients were eligible for treatment with 80 mg IXE Q4W when improvement in Psoriasis Area and Severity Index score from baseline was ≤75%); <sup>c</sup> Protocol amendment–mandated dose regimen; <sup>d</sup> PBO administered to maintain study blind; <sup>e</sup> Step-up criteria determined if dosing increased from 80 mg IXE Q4W to 80 mg IXE Q2W for a patient who achieved static Physician's Global Assessment ≥2 at 2 consecutive visits during Wk 12 through Wk 40; <sup>f</sup> Based on investigator opinion, dosing increased from IXE Q4W to IXE Q2W between Wk 24 through Wk 40; <sup>g</sup> Subcutaneous injection of 160 mg starting dose (two 80 mg injections). Exclusion criteria related to malignancies:

\* Patients with active or a history of or signs or symptoms of malignant disease were excluded. Patients with successfully treated BCC (no more than 3), SCC of the skin §, cervical carcinoma in situ, with no evidence of recurrence within 5 years of baseline (Week 0; Visit 2) were allowed to participate.

§ SCC of the skin (no more than 2).

† Patients with active or a history of or signs or symptoms of malignant disease within 5 years prior to baseline (Week 0; Visit 2) were excluded. Patients with history of malignancy with no evidence of recurrence or active disease within 5 years prior to baseline were allowed to participate.


¥ Patients with active or a history of or signs or symptoms of malignant disease within 5 years prior to baseline (Week 0; Visit 2) except for BCC, SCC, skin Bowen's disease or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks or carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed. Patients with history of malignancy with no evidence of recurrence or active disease within 5 years of baseline may participate in the study.

¶ Patients with current or a history of lymphoproliferative disease or a primary or recurrent malignant disease.

<u>Abbreviations:</u> AC, active comparator; DB, double-blind; EP, optional extension period after Wk 24 during which patients received 80 mg IXE Q4W up to Wk 60; ETN, 50 mg etanercept twice weekly; FAE, fumaric acid esters 105-mg starting dose followed by 215 mg given orally 1–3 times per day; GUS, guselkumab 100 mg at Wk 0, Wk 4, then Q8W; IXE, ixekizumab; IXE Q2W, ixekizumab every 2 weeks; IXE Q4W, ixekizumab every 4 weeks; IXE Q12W, ixekizumab every 12 weeks; LTE, long-term extension; MTX, methotrexate 7.5-mg starting dose up to 30 mg given orally once a week; N, number of patients; OL, open-label; PAC, placebo-controlled and active comparator; PASI, Psoriasis Area Severity Index; PBO, placebo; Q2W Every 2 weeks, Q4W Every 4 weeks; R, randomized; sPGA, Static Physician's Global Assessment; UST, 45 mg ustekinumab given as subcutaneous injection for participants > 100 kg at weeks 0, 4, 16, 28 and 40, Wk week.


Information from Figure 1 of Armstrong et al, 2020<sup>20</sup> are included in this figure.

Supplemental figure 1 has been created by Lilly, including some of the information presented previously in Figure 1 of Armstrong et al, 2020. New information is also presented. Full reference: Armstrong, A., Paul, C., Puig, L. et al. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatol Ther (Heidelb) 10, 133–150 (2020). <u>https://doi.org/10.1007/s13555-019-00340-3</u>



Supplemental Figure 2. Treatment-emergent skin cancer events by yearly interval from all IXE trials.

Incidence rate of malignant skin neoplasms (a), NMSC (b), SCC (c) and BCC (d). Abbreviations: BCC = basal cell carcinoma; Ixe = ixekizumab; N = Total number of patients; n = number of patients per category; NMSC = non-melanoma skin cancer; IR = incidence rate; PBO = placebo; SCC = squamous cell cancer. Supplemental Figure 3. Treatment-emergent skin cancer events from the placebo-controlled induction period of UNCOVER-1, UNCOVER-2 and UNCOVER-3.



Incidence rate of malignant skin neoplasms (a), NMSC (b), SCC (c) and BCC (d). Treatment-emergent skin cancer events from all ixezumab trials included in this study are shown (right; A-D) Abbreviations: BCC = basal cell carcinoma; Ixe = ixekizumab; N = Total number of patients; n = number of patients per category; NMSC = non-melanoma skin cancer; IR = incidence rate; PBO = placebo; SCC = squamous cell cancer.

# Supplemental table 1. Time to onset (days) of skin cancer TEAEs.

Category	N	Mean	SD
Patients with >=1 TEAE	58	676	585
Nonmelanoma skin cancer	55	682	573
Basal cell carcinoma	44	621	539
Squamous cell carcinoma	16	820	619
Bowen's disease	4	936	334
Keratoacanthoma	1	51	NA
Lip squamous cell carcinoma	2	715	462
Squamous cell carcinoma	7	977	670
Squamous cell carcinoma of skin	8	334	580
Melanoma	2	842	1130
Malignant Melanoma	1	43	NA
Malignant Melanoma in situ	1	1641	NA
Other skin neoplasms	1	13	NA
Dermatofibrosarcoma protuberans	1	13	NA

N = number of patients per category; SD = standard deviation; TEAE = treatment-emergent adverse events; BCC.